- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05045495
Adult Pilot Study for Reference Ranges and Optimal Cut-offs for the Sucrose Challenge Test and Sucrose Breath Test
Adult Pilot Study to Establish the Reference Ranges and Optimal Cut-offs for Oral 50g Sucrose Challenge Test & 13C-Sucrose Breath Test for CSID Cases (Previously Diagnosed Sucraid Responders) & Controls (GI Asymptomatic Healthy Volunteers)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In an effort to mimic the real-world diagnostic setting for these tests, this study will be conducted virtually using a central site with telemedicine capabilities and electronic data capture software to collect data in real time via a mobile app. Subject will complete 3 visits within 21 days. Eligible subjects will undergo the following tests:
- 50g 13C-Sucrose Breath Test (CBT)
- Sucrose Intolerance Hydrogen Methane Breath Test (HBT)
- Sucrose Challenge Test (SCT)
- Buccal swab for CSID Genetic Testing (GT)
The primary aim is to establish the reference/normal ranges and optimal cutoff values for the SCT and CBT.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
California
-
Culver City, California, United States, 90230
- Science 37-Recruiting Nationally
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Subject must provide informed consent prior to any study procedures being performed.
- Subject is a U.S. resident, and speaks and understands English
- Subject is male or female, ≥ 18 years old.
- CSID Cases must have been on Sucraid for at the last 12 months.
- Healthy Volunteers do not have a CSID diagnosis or other chronic gastrointestinal conditions.
- Subject must have their own Android or Apple device to access the mobile patient app.
Exclusion Criteria:
- Females who are lactating or pregnant.
- Subjects with allergy to sucrose.
- Subjects with causes of abdominal pain or altered bowel habits other than symptoms -related to CSID (in CSID group) such as SIBO, IBD, celiac disease, pancreatitis, or -gastrointestinal bleeding.
- Diabetes mellitus.
- Use of systemic antibiotics, had a barium study, colonoscopy, unexplained runny diarrhea, or similar within 14 days prior to informed consent. Potential subjects can be re-screened once they meet this criterion.
- Recent febrile illness.
- Subject has major physical or psychiatric illness within the last 6 months that in the opinion of the investigator would affect the subject's ability to complete the trial.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Healthy Volunteer
120 Healthy Volunteers will perform the 50-gram sucrose challenge test, Sucrose hydrogen methane breath test, 13C-sucrose breath test and collect buccal swab samples for genetic testing.
|
Subjects will collect 2 buccal swabs for the sucrase genetic test and then subjects will simultaneously conduct the sucrose challenge test, sucrose hydrogen methane breath test, and the 13C-sucrose following ingestion of 50-grams of sucrose (table sugar) mixed with 8 ounce of water.
Other Names:
|
|
CSID Case
50 CSID cases defined by being on Sucraid for at least 12 months will perform the 50-gram sucrose challenge test, Sucrose hydrogen methane breath test, 13C-sucrose breath test and collect buccal swab samples for genetic testing.
|
Subjects will collect 2 buccal swabs for the sucrase genetic test and then subjects will simultaneously conduct the sucrose challenge test, sucrose hydrogen methane breath test, and the 13C-sucrose following ingestion of 50-grams of sucrose (table sugar) mixed with 8 ounce of water.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Establish the normal reference range for the 50g Sucrose Challenge Test (SCT)
Time Frame: 4 hours post ingestion of sucrose
|
Reference ranges will be estimated by the lower 2.5th percentile and upper 97.5th percentile of the distribution of test results for the case and control populations.
|
4 hours post ingestion of sucrose
|
|
Establish the optimal cutoff values for the 50g Sucrose Challenge Test (SCT)
Time Frame: 4 hours post ingestion of sucrose
|
The mean and peak symptom severity score following sucrose ingestion will serve as markers of sucrase activity.
The cutoff for the SCT will be determined by the maximum Youden Index that differentiates cases and controls.
|
4 hours post ingestion of sucrose
|
|
Establish the normal reference range for the 50g 13C-Sucrose Breath Test (CBT)
Time Frame: 4 hours post ingestion of sucrose
|
Reference ranges will be estimated by the lower 2.5th percentile and upper 97.5th percentile of the distribution of test results for the case and control populations.
|
4 hours post ingestion of sucrose
|
|
Establish the optimal cutoff values for the 50g 13C-Sucrose Breath Test (CBT)
Time Frame: 4 hours post ingestion of sucrose
|
The mean and peak symptom severity score following sucrose ingestion will serve as markers of sucrase activity.
The cutoff for the SCT will be determined by the maximum Youden Index that differentiates cases and controls.
|
4 hours post ingestion of sucrose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Compare the positive predictive values (PPV) of the Sucrose Challenge Test (SCT) with the PPV of the Sucrose Hydrogen Methane Breath Test (HBT)
Time Frame: 4 hours post ingestion of sucrose
|
PPV of SCT relative to the HBT and percentage of Sucraid® Responders in CSID cases and asymptomatic controls, and in cases confirmed by each of the following three diagnostic tools: HBT, CBT, and SCT.
|
4 hours post ingestion of sucrose
|
|
Compare the negative predictive values (NPV) of the Sucrose Challenge Test (SCT) with the NPV of the Sucrose Hydrogen Methane Breath Test (HBT)
Time Frame: 4 hours post ingestion of sucrose
|
NPV of SCT relative to the HBT and percentage of Sucraid® Responders in CSID cases and asymptomatic controls, and in cases confirmed by each of the following three diagnostic tools: HBT, CBT, and SCT.
|
4 hours post ingestion of sucrose
|
|
Compare the positive predictive values (PPV) of the 13C-Sucrose Breath Test (CBT) with the positive predictive value of the Sucrose Hydrogen Methane Breath Test (HBT)
Time Frame: 4 hours post ingestion of sucrose
|
PPV of the CBT relative to the HBT and percentage of Sucraid® Responders in CSID cases and asymptomatic controls, and in cases confirmed by each of the following three diagnostic tools: HBT, CBT, and SCT.
|
4 hours post ingestion of sucrose
|
|
Compare the negative predictive value (NPV) of the 13C-Sucrose Breath Test (CBT) with the NPV of the Sucrose Hydrogen Methane Breath Test (HBT)
Time Frame: 4 hours post ingestion of sucrose
|
NPV of the CBT relative to the HBT and percentage of Sucraid® Responders in CSID cases and asymptomatic controls, and in cases confirmed by each of the following three diagnostic tools: HBT, CBT, and SCT.
|
4 hours post ingestion of sucrose
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- SSDXA-12
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Congenital Sucrase-Isomaltase Deficiency
-
QOL Medical, LLCTerminatedCongenital Sucrase-Isomaltase Deficiency | CSID | Sucrase Isomaltase DeficiencyUnited States
-
Region SkaneRegion Skåne FoUURecruitingIBS - Irritable Bowel Syndrome | Sucrase-Isomaltase DeficiencySweden
-
Nottingham University Hospitals NHS TrustCICbioGUNE; Christian-Albrechts-University of Kiel; University of Veterinary...Active, not recruitingIrritable Bowel Syndrome (IBS) | Sucrase Isomaltase DeficiencyUnited Kingdom
-
QOL Medical, LLCJohns Hopkins University; Massachusetts General Hospital; Baylor College of Medicine and other collaboratorsCompletedCongenital Sucrase-isomaltase Deficiency (CSID)United States
-
University of NottinghamInstitute for Clinical Molecular Biology, Christian-Albrechts-University,... and other collaboratorsNot yet recruitingSucrase Isomaltase DeficiencyUnited Kingdom
-
Steno Diabetes Center CopenhagenThe Novo Nordisk Foundation Center for Basic Metabolic Research; Department... and other collaboratorsCompletedDiabetes Mellitus, Type 2 | Metabolic Disease | Sucrase Isomaltase Deficiency | Sucrose Intolerance CongenitalGreenland
-
QOL Medical, LLCWithdrawn
-
Lovisenberg Diakonale HospitalUniversity of BergenNot yet recruitingIrritable Bowel Syndrome | Functional Gastrointestinal Disorders | Sucrase Isomaltase Deficiency | Sucrose Intolerance Due to Sucrase-Isomaltase Deficiency | Carbohydrate; Malabsorption
-
Region SkaneCompletedIrritable Bowel Syndrome | Sucrase-Isomaltase DeficiencySweden
-
Indiana Hemophilia &Thrombosis Center, Inc.Fondazione Angelo Bianchi BonomiRecruitingPlasminogen DeficiencyUnited States, Canada, Thailand, Argentina, Australia, Italy, Austria, Greece, Israel, Turkey (Türkiye), United Kingdom
Clinical Trials on Sucrose Hydrogen Methane Breath Test
-
Zhongshan Hospital (Xiamen), Fudan UniversityCompletedHelicobacter Pylori Infection | Gut Microbiota | Small Intestinal Bacterial Overgrowth | Metabolic ProfilesChina
-
Yonsei UniversityUnknownIrritable Bowel SyndromeKorea, Republic of
-
VenterPharmaCompleted
-
University of Novi Sad, Faculty of Sport and Physical...CompletedMetabolic SyndromeSerbia
-
University of IoanninaCompletedCritical Illness | Intensive Care Unit | Small Intestinal Bacterial OvergrowthGreece
-
Asian Institute of Gastroenterology, IndiaRecruitingIrritable Bowel Syndrome | Small Bowel Disease | Motility DisorderIndia
-
Brain-Gut Research GroupNational University, Singapore; New Jersey Medical SchoolCompletedIrritable Bowel Syndrome | Functional Gastrointestinal DisordersSwitzerland
-
Mebo Research, Inc.Aurametrix; Menssana Research, Inc.CompletedNutritional and Metabolic DiseasesUnited States, United Kingdom
-
Imperial College LondonUniversity College London Hospitals; Northern Care Alliance NHS Foundation... and other collaboratorsRecruitingBarrett Esophagus | Oesophageal Cancer | Barretts Esophagus With DysplasiaUnited Kingdom